
|Videos|March 15, 2011
Dr. Berenson on the Study of Zometa in Multiple Myeloma
Author(s)James R. Berenson, MD
James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.
Advertisement
James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum
2
Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings
3
Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL
4
Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD
5






































































